The Phase 3 clinical trial comparing Tofacitinib and prednisolone for the treatment of active Takayasu's arteritis reached its primary completion on 2025-07-20. This milestone indicates that the study has completed the collection of data for its primary outcome measures, moving closer to the release of results.
Background
Tofacitinib (also known by its brand names Xeljanz and Xeljanz XR) is being evaluated in this study for its potential to treat active Takayasu's arteritis. This trial specifically compares tofacitinib's clinical efficacy and safety against another treatment, prednisolone, in patients with this condition.
Trial design
The study, officially registered as NCT05749666, is a Phase 3, prospective, double-blinded, single-center, randomized clinical trial. It enrolled 50 participants who have been diagnosed with active Takayasu's arteritis. The trial's design involves comparing the clinical efficacy and safety of tofacitinib 5 mg with prednisolone. The primary objective is to assess these two drugs in the treatment of active Takayasu's arteritis patients.
What this means
The primary completion of this Phase 3 trial represents a significant step forward in the clinical evaluation of tofacitinib for active Takayasu's arteritis. This milestone suggests that all data required for the primary endpoint analysis has been collected. The forthcoming results are expected to provide crucial insights into the comparative efficacy and safety profile of tofacitinib when measured against prednisolone for this challenging condition, informing future treatment decisions for clinicians and patient advocates.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT05749666, titled 'Comparison of Tofacitinib and Prednisolone in the Treatment of Active Takayasu's Arteritis,' was updated to reflect primary completion on 2025-07-20 on clinicaltrials.gov.